Table 2 Pharmacological treatment of patients with systemic lupus erythematosus included in the study at the time the lumbar puncture was performed
Treatment | NPSLE (n = 43) | No NPSLE (n = 71) | aPL syndrome (n = 9) |
|---|---|---|---|
Prednisolone (≤10 mg) | 18 | 37 | 3 |
Prednisolone (>10 mg) | 7 | 8 | 0 |
No prednisolone | 18 | 23 | 5 |
Antimalarials | 1 | 8 | 0 |
Azathioprine | 5 | 10 | 3 |
Azathioprine + cyclosporin A | 2 | 3 | 0 |
Azathioprine + antimalarials | 0 | 0 | 0 |
Methotrexate | 5 | 1 | 0 |
Cyclosporin A | 0 | 6 | 1 |
Cyclophosphamide | 14 | 10 | 0 |
Cyclophosphamide + cyclosporin A | 3 | 0 | 0 |
Cyclophosphamide + antimalarials | 0 | 1 | 0 |
No cytotoxic drug | 11 | 30 | 4 |
Antihypertensive treatment | 14 | 15 | 2 |
Low-dose aspirin | 8 | 19 | 3 |
Warfarin | 3 | 2 | 2 |